When cancer cells carry a mutation in the KRAS gene, the disease becomes both more challenging and, paradoxically, more targetable. For decades, doctors and researchers faced a puzzle: how to treat cancers driven by this common genetic change. Today, new treatments are emerging that offer hope where once there was only frustration, though the journey is far from over.

What Happens When Cancer Meets KRAS

The KRAS gene sits quietly in our cells, acting as a molecular switch that controls when cells grow, divide, or die. Under normal circumstances, this gene produces a protein that behaves like a responsible traffic light—sometimes green, allowing cell growth, sometimes red, stopping it. The protein switches on when it binds to a molecule called GTP, and switches off when it converts GTP to another molecule called GDP.^[1]

But when the KRAS gene mutates, everything changes. The mutation essentially jams the switch in the “on” position. The mutated protein keeps signaling cells to grow and multiply without stopping, even when they should rest or die. This runaway growth is one of the fundamental mechanisms behind many cancers.^[4]

KRAS mutations are remarkably common across different cancer types. In colorectal cancer, roughly 40 to 45 percent of tumors carry a KRAS mutation. In non-small cell lung cancer, the figure ranges from 15 to 25 percent among all patients, though it can be as high as 50 percent in white populations. The most striking statistic comes from pancreatic cancer, where more than 90 percent of tumors harbor KRAS mutations.^[3][16][5]

These mutations don’t just drive cancer growth—they also change how the disease behaves and responds to treatment. The mutation occurs during a person’s lifetime within tumor cells themselves. It is not inherited from parents, which means family members don’t automatically face increased risk. However, once present in a tumor, the KRAS mutation often signals a more aggressive disease course and resistance to certain therapies.^[3][8]

Finding Out: The Role of Biomarker Testing

When someone receives a cancer diagnosis, particularly lung, colorectal, or pancreatic cancer, one of the first and most crucial steps involves testing the tumor for genetic mutations. This process, called biomarker testing or molecular profiling, examines the tumor’s genetic makeup to identify specific changes that might be driving cancer growth.^[5]

Testing for KRAS mutations typically requires a small tissue sample from the tumor, obtained either through a biopsy (removing a small piece of tissue with a needle or surgical instrument) or during surgery to remove the tumor. In some cases, doctors can also test blood samples for fragments of tumor DNA circulating in the bloodstream—a technique called liquid biopsy. The sample is then sent to a laboratory where technicians analyze the tumor’s DNA to detect any KRAS mutations and identify the specific subtype.^[5][8]

The test results come back reporting either “KRAS wild-type,” meaning no mutation is present, or “KRAS mutant” with the specific change identified, such as “KRAS G12C” or “KRAS G12V.” This information becomes a cornerstone of the treatment plan. Testing may be performed individually or as part of a larger panel that examines multiple genes at once using next-generation sequencing, which can provide a more comprehensive picture of the tumor’s biology.^[5][17]

Ideally, biomarker testing should happen before any treatment begins, including chemotherapy or immunotherapy. The results may take one to two weeks to return, but waiting for this information is usually worthwhile, as it can fundamentally change the treatment approach. Many cancer centers, particularly those designated by the National Cancer Institute, have experience with comprehensive biomarker testing and can guide patients through the process.^[8]

Standard Treatment When KRAS Is Involved

For many years, having a KRAS mutation meant fewer treatment options and often a poorer outlook. The mutation affects how cancers respond to various therapies, sometimes making treatments less effective or completely ineffective. Understanding these limitations has been as important as developing new solutions.

In colorectal cancer with wild-type KRAS (no mutation present), doctors can use a class of drugs called EGFR inhibitors, such as cetuximab (Erbitux) or panitumumab (Vectibix). These medications work by blocking a protein on the cell surface that normally receives growth signals. However, when KRAS is mutated, it bypasses this surface protein entirely by staying constantly activated inside the cell. As a result, blocking EGFR becomes pointless—the growth signals continue regardless. Patients with KRAS-mutated colorectal cancer cannot benefit from EGFR inhibitors and should not receive them.^[5][4]

Chemotherapy remains a cornerstone of treatment for KRAS-mutated cancers. In lung cancer, standard chemotherapy combinations typically include platinum-based drugs like cisplatin or carboplatin paired with other agents such as pemetrexed or paclitaxel. These drugs work by damaging DNA or disrupting cell division, affecting both cancer cells and some healthy rapidly dividing cells. The treatment usually continues for several cycles, with each cycle lasting three to four weeks.^[4][13]

Chemotherapy side effects can be substantial and vary depending on the specific drugs used. Common problems include fatigue, nausea and vomiting, hair loss, increased infection risk due to low white blood cell counts, and numbness or tingling in hands and feet (a condition called peripheral neuropathy). Doctors can often manage these side effects with supportive medications and adjustments to dosing or timing.

Immunotherapy has revolutionized cancer treatment in recent years, but its effectiveness in KRAS-mutated cancers depends on other factors. These treatments, such as pembrolizumab (Keytruda) or nivolumab (Opdivo), work by unleashing the immune system to attack cancer cells. In lung cancer, immunotherapy is now commonly used either alone or combined with chemotherapy as first-line treatment, regardless of KRAS status. The presence of KRAS mutations doesn’t necessarily predict how well immunotherapy will work—other biomarkers, particularly PD-L1 expression and tumor mutational burden, matter more for these decisions.^[4][13]

Side effects from immunotherapy differ from chemotherapy’s effects. Because these drugs activate the immune system, they can cause immune-related adverse events where the immune system attacks normal tissues. This might affect the lungs (causing pneumonitis), colon (colitis), liver (hepatitis), skin (rash), or hormone-producing glands (thyroid problems or diabetes). While often less severe than chemotherapy side effects, immune-related problems can sometimes be serious and require prompt treatment with steroids or other immune-suppressing medications.

Anti-angiogenic drugs, such as bevacizumab (Avastin), represent another treatment option. These medications work by blocking the formation of new blood vessels that feed tumors. In colorectal cancer, bevacizumab can be combined with chemotherapy regardless of KRAS status. Side effects may include high blood pressure, protein in urine, bleeding problems, and delayed wound healing.^[4]

Radiation therapy and surgery also play important roles, particularly for localized disease or specific sites of spread. The treatment plan depends heavily on the cancer’s stage, location, and how far it has spread, as well as the patient’s overall health and preferences.

The Breakthrough: Targeted Drugs in Clinical Trials

For nearly four decades after KRAS was first identified in 1982, it earned a reputation as “undruggable.” The protein’s smooth, spherical surface seemed to offer nowhere for drugs to grip. Scientists searched in vain for pockets or grooves where a medication could bind and disable the mutant protein. This challenge meant that while other cancer-driving mutations became targets for successful drugs, KRAS remained frustratingly out of reach.^[4][6]

The breakthrough came about a decade ago when researchers discovered something remarkable: the G12C form of mutant KRAS briefly forms a small pocket that doesn’t exist in the normal protein or other KRAS mutations. More importantly, they found that certain molecules could slip into this pocket and essentially lock the protein in its inactive, GDP-bound state. This discovery opened the door to developing the first generation of KRAS inhibitors.^[6]

KRAS G12C Inhibitors: From Lab to Approval

The first KRAS G12C inhibitor to gain approval was sotorasib (Lumakras), authorized by the U.S. Food and Drug Administration in 2021 for adults with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer who have received at least one prior systemic therapy. This approval marked a historic moment—the first drug specifically targeting a KRAS mutation in any cancer type.^[4][17]

Sotorasib works by covalently binding—forming a permanent chemical bond—to the mutant KRAS G12C protein, trapping it in an inactive state. Clinical trials showed that about 40 percent of lung cancer patients treated with sotorasib experienced tumor shrinkage, with responses lasting an average of about 11 months. The drug is taken orally as a pill, once daily, making it convenient compared to intravenous chemotherapy.^[13]

Common side effects of sotorasib include diarrhea, muscle and bone pain, nausea, fatigue, and liver enzyme elevations detected in blood tests. Most side effects are manageable, though some patients require dose reductions. Serious but less common problems can include liver toxicity and lung inflammation.

Shortly after sotorasib, a second KRAS G12C inhibitor called adagrasib (Krazati) received FDA approval in 2022, also for KRAS G12C-mutated lung cancer. Adagrasib works through a similar mechanism, covalently binding to the mutant protein. In clinical trials, roughly 43 percent of patients experienced tumor shrinkage, with responses lasting about eight to nine months. Like sotorasib, adagrasib is taken orally, though it requires twice-daily dosing.^[4][13]

Side effects of adagrasib overlap with sotorasib’s profile but may be somewhat more frequent. Nausea, diarrhea, vomiting, and fatigue are common. Liver enzyme elevations also occur and require monitoring. The twice-daily schedule may be less convenient for some patients but allows for more steady drug levels in the blood.

Notably, the FDA also approved adagrasib in combination with cetuximab (the EGFR inhibitor) for adults with KRAS G12C-mutated colorectal cancer that has spread beyond the colon. This represents the first approved treatment specifically targeting KRAS in colorectal cancer. The combination approach appears to work better than adagrasib alone in this cancer type, though it comes with side effects from both drugs.^[12][17]

Beyond G12C: Targeting Other KRAS Mutations

While G12C inhibitors represent a major achievement, the G12C mutation accounts for only about 13 to 14 percent of KRAS mutations in lung cancer and even smaller percentages in other cancers. Most KRAS-mutated cancers have different subtypes—G12D, G12V, G13D, and others—that cannot be treated with current approved drugs. Developing inhibitors for these other mutations remains an active area of research.^[4][17]

Several investigational drugs targeting non-G12C KRAS mutations are now in early-phase clinical trials. These trials typically begin with Phase I studies focused on determining safe doses and identifying side effects. If a drug appears safe and shows signs of activity, it moves to Phase II trials testing effectiveness in larger groups of patients. Finally, Phase III trials compare the new treatment against standard options to determine if it offers superior outcomes.

Some of these newer drugs take different approaches than the G12C inhibitors. Rather than locking KRAS in an inactive state, certain experimental compounds prevent the mutant protein from properly attaching to the cell membrane where it needs to be to send growth signals. Others work by blocking proteins that interact with mutant KRAS, essentially cutting off its support network. While still in early testing phases, preliminary results from some of these trials have shown tumor shrinkage in patients whose cancers carry G12D, G12V, and other mutations.^[4][18]

Gene Therapy Approaches

Beyond small-molecule drugs that bind to the mutant protein, researchers are exploring gene therapy strategies that work at the genetic level. These approaches aim to either silence the mutated KRAS gene, replace it with a normal version, or use the mutation itself as a target for immune attack.^[18]

One promising direction involves using short pieces of genetic material called siRNA (small interfering RNA) or antisense oligonucleotides to specifically block the production of mutant KRAS protein. These molecules are designed to recognize and bind to the mutant KRAS genetic message, preventing it from being translated into protein. The challenge lies in delivering these molecules specifically to cancer cells throughout the body.

Another gene therapy concept uses modified viruses or nanoparticles (tiny engineered particles) as delivery vehicles to carry therapeutic genes or molecules directly into tumor cells. Early studies in laboratory models have shown that these delivery systems can successfully reduce mutant KRAS protein levels and slow tumor growth, but translating these findings to human patients remains challenging.^[18]

These gene-based therapies are still largely in preclinical development or very early clinical testing. They represent a longer-term research direction rather than near-term treatment options, but their development could eventually provide alternatives for patients whose cancers don’t respond to current drugs.

Combination Strategies and Immunotherapy Partnerships

A major lesson from treating KRAS-mutated cancers is that single-drug approaches often face resistance. Cancer cells prove remarkably adaptable, finding ways around the blockade created by KRAS inhibitors. Researchers discovered that tumors treated with KRAS G12C inhibitors sometimes activate alternative growth pathways or develop new mutations that restore cancer cell survival despite the drug.^[4][13]

This realization has driven extensive research into combination therapies. Clinical trials are now testing KRAS inhibitors paired with chemotherapy, immunotherapy, other targeted drugs, or multiple combinations at once. The goal is to attack the cancer from several angles simultaneously, making it harder for resistance to develop.

One particularly innovative approach combines KRAS-targeted therapy with immunotherapy in an unexpected way. Researchers discovered that when KRAS inhibitors bind to the mutant protein inside cancer cells, fragments of this drug-protein complex can appear on the cell surface. Scientists have engineered special antibodies that recognize these surface fragments and flag the cancer cells for destruction by the immune system. In early laboratory studies, this approach helped overcome resistance to KRAS inhibitors and enlisted immune cells to kill cancer cells that might otherwise survive the targeted therapy.^[10]

Clinical trials combining KRAS G12C inhibitors with checkpoint inhibitor immunotherapy drugs (like pembrolizumab or nivolumab) are ongoing. Early results suggest that some patients may benefit from this combination, though side effects from both types of drugs must be carefully managed. These trials are being conducted at major cancer centers in the United States, Europe, and other regions.^[13]

Where Trials Are Happening and Who Can Join

Clinical trials testing new KRAS-targeted treatments are being conducted at cancer centers across the United States, throughout Europe, and in other countries worldwide. Major academic medical centers and National Cancer Institute-designated comprehensive cancer centers often have multiple KRAS-related trials available.

Eligibility for trials depends on several factors: the specific type of cancer, which KRAS mutation is present, what prior treatments the patient has received, the extent of disease spread, and overall health status. Most trials require documented confirmation through biomarker testing that the tumor carries the specific KRAS mutation being targeted by the investigational drug.

Some trials focus exclusively on patients whose cancer has progressed after standard treatments, providing options when other therapies have failed. Others test new drugs as earlier lines of treatment, potentially offering more effective options before resistance to standard therapies develops. Trials may also have specific requirements regarding organ function, particularly kidney and liver health, to ensure patients can safely metabolize and eliminate the experimental drugs.

Most common treatment methods

• Chemotherapy
  • Platinum-based combinations with cisplatin or carboplatin paired with agents like pemetrexed or paclitaxel
  • Standard first-line treatment for many KRAS-mutated lung and colorectal cancers
  • Treatment typically given in cycles lasting three to four weeks
  • Side effects include fatigue, nausea, hair loss, increased infection risk, and nerve damage
• Immunotherapy
  • Checkpoint inhibitors such as pembrolizumab (Keytruda) or nivolumab (Opdivo)
  • Work by activating the immune system to attack cancer cells
  • Can be used alone or combined with chemotherapy in lung cancer
  • Effectiveness depends more on PD-L1 expression and tumor mutational burden than KRAS status
  • Side effects involve immune system overactivation affecting normal tissues
• KRAS G12C Inhibitors
  • Sotorasib (Lumakras) approved in 2021 for KRAS G12C-mutated lung cancer
  • Adagrasib (Krazati) approved in 2022 for lung cancer and in combination for colorectal cancer
  • First drugs specifically targeting a KRAS mutation
  • Work by locking the mutant protein in an inactive state
  • Taken as oral pills, offering convenience over intravenous treatments
  • Response rates around 40-43 percent with responses lasting months
• EGFR Inhibitors (for wild-type KRAS)
  • Cetuximab (Erbitux) and panitumumab (Vectibix) for colorectal cancer without KRAS mutation
  • Block growth signals at the cell surface
  • Not effective when KRAS is mutated, as the mutation bypasses this pathway
  • Can be combined with adagrasib for KRAS G12C-mutated colorectal cancer
• Anti-angiogenic Therapy
  • Bevacizumab (Avastin) blocks formation of blood vessels feeding tumors
  • Can be combined with chemotherapy regardless of KRAS status
  • Used in colorectal and lung cancers
  • Side effects include high blood pressure, bleeding problems, and delayed wound healing
• Combination Approaches in Clinical Trials
  • KRAS inhibitors combined with chemotherapy to attack cancer from multiple angles
  • KRAS inhibitors paired with immunotherapy to overcome resistance
  • Combinations of targeted drugs blocking different pathways
  • Antibody-drug conjugates that use KRAS-drug complexes to recruit immune attack
  • Testing is ongoing in Phase I, II, and III clinical trials worldwide
• Gene Therapy (Experimental)
  • siRNA and antisense oligonucleotides to silence mutant KRAS gene expression
  • Modified viruses or nanoparticles to deliver therapeutic molecules to cancer cells
  • Approaches to use KRAS mutation as a target for immune recognition
  • Still largely in preclinical or very early clinical development
• Radiation Therapy and Surgery
  • Used for localized disease or specific sites of cancer spread
  • Often combined with systemic treatments like chemotherapy or targeted therapy
  • Role depends on cancer stage, location, and overall treatment goals